Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D2-like receptor and α1/α2-adrenoceptor

Journal of Pharmacology and Experimental Therapeutics

Volumn 303, Issue 2, 2002, Pages 805-814

  Newman Tancredi, Adrian ^a   Cussac, Didier ^a   Audinot, Valérie ^b   Nicolas, Jean Paul ^a   De Ceuninck, Frédéric ^a   Boutin, Jean A ^b   Millan, Mark J ^a  

^a Department of Psychopharmacology ^*  (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIMETHYLAMINO 6,7 DIHYDROXYTETRALIN; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ANTIPARKINSON AGENT; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; DOPAMINE 2 RECEPTOR; LISURIDE; PERGOLIDE; PIRIBEDIL; PRAMIPEXOLE; QUINELORANE; QUINPIROLE; ROPINIROLE; ROXINDOLE; TALIPEXOLE; TERGURIDE;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ALPHA ADRENERGIC STIMULATION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DOPAMINE RECEPTOR BLOCKING; DRUG ACTIVITY; DRUG EFFICACY; DRUG RECEPTOR BINDING; MULTIVARIATE ANALYSIS; NONHUMAN; PARKINSON DISEASE; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL;

ANIMALS; ANTIPARKINSON AGENTS; CHO CELLS; CRICETINAE; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; KINETICS; PHOSPHATIDYLINOSITOLS; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, DOPAMINE D4;

EID: 0036828226     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.039875     Document Type: Article

References (57)

1. 2 agonist on MPTP-lesioned parkinson cynomolgus monkeys. Ann Neurol 33:507-511.
2. 2LONG dopamine receptors in human neuroblastoma SH-SY5Y over human embryonic kidney 293 cells. Br J Pharmacol 131:514-520.
3. Arnsten AFT (1997) Catecholamine regulation of the prefrontal cortex. J Psychopharmacol 11:151-162.
4. 4 receptor antagonist, PNU-101387G, prevents stress-induced cognitive deficits in monkeys. Neuropsychopharmacology 23:405-410.
5. 2 agonists with high and low efficacies: Differentiation by behavioural techniques. J Neural Transm [Gen Sect] 80:33-50.
6. Bezard E, Brotchie JM, and Gross CE (2001) Pathophysiology of Levo-dopa induced dyskinesia: Potential for new therapies. Nat Rev Neurosci 2:577-588.
7. 2C-adrenoceptors impairs water maze navigation. Neuroscience 95:481-487.
8. 2-adrenoceptors control excitatory, but not inhibitory, transmission at rat hippocampal synapses. J Physiol (Lond) 519:439-449.
9. 2-Adrenoceptor antagonists: A new approach to Parkinson's Disease? CNS Drugs 10:189-207.
10. 4.4 receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 127:1696-1702.
11. 2L receptors revealed by G protein but not MAP-kinase activation. 32th Society for Neuroscience Meeting (USA), in press.
12. 2 dopamine receptor agonist. Psychopharmacology 113:172-176.
13. Filipova M, Filip V, Macek Z, Mullerova S, Markova J, Kas S, Zizkova B, Krivka J, Votavova M, and Krejcova H (1988) Terguride in parkinsonism. A multicenter trial. Eur Arch Psychiatry Neurol Sci 237:298-303.
14. 2(short) dopamine receptors determined in ligand binding and functional assays. J Neurochem 69:2589-2598.
15. 2(long) dopamine receptors: Ligand binding and functional assays. Br J Pharmacol 124:978-984.
16. 4 receptor. Naunyn-Schmiedeberg's Arch Pharmacol 361:555-564.
17. 35S] GTPγS binding in striatum of 6-hydroxydopamine-lesioned rats. Brain Res 841:135-142.
18. 35S]GTPγS binding assays. Naunyn-Schmiedeberg's Arch Pharmacol 361:498-504.
19. 3 receptor expression and triggers behavioural sensitization. Nature (Lond) 411:86-89.
20. Guimarães S and Moura D (2001) Vascular adrenoceptors: An update. Pharmacol Rev 53:319-356.
21. Horn AS, De Vries J, Dijkstra D, and Mulder AH (1982) Is TL99 a selective presynaptic dopamine receptor agonist? Eur J Pharmacol 83:35-45.
22. Hughes AJ (1997) Drug treatment of Parkinson's disease in the 1990s: Achievements and future possibilities. Drugs 53:195-205.
23. 2-antagonistic effects of some dopamine receptor agonists and antagonists. Naunyn-Schmiedeberg's Arch Pharmacol 330:105-113.
24. 3 receptors as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol Ther 90:231-259.
25. 2-adrenergic receptors. J Pharmacol Exp Ther 293:1-7.
26. Kostrzewa RM (1995) Dopamine receptor supersensitivity. Neurosci Biobehav Rev 19:1-17.
27. Langtry HD and Clissold SP (1990) Pergolide: A review of its pharmacological properties and therapeutic potential in Parkinson's disease. Drugs 39:491-506.
28. B from inhibtion curves in functional experiments: Alternatives to the Cheng- Prusoff equation. Trends Pharmacol Sci 14:237-239.
29. Martin GE, Jones JH, and Bendesky RJ (1983) Different actions of TL-99 and 3-PPP in producing contraversive turning in the 6-OHDA-lesioned rat. Eur J Pharmacol 92:275-278.
30. Maurin B, Baunez C, Bonhomme C, Chezaubernard C, Nieoullon A, and Amalric M (2001) Cognitive deficits in 6-OHDA lesioned rats are improved by chronic treatment with the dopamine agonist, piribedil. Behav Pharmacol 12:S63.
31. 2 agonists and antagonists. Brain Res 562:216-224.
32. 2-adrenoceptors. Eur J Pharmacol 97:151-155.
33. 2-adrenoceptor antagonists idazoxan and yohimbine can unmask the postsynaptic dopamine agonist effects of B-HT 920. Eur J Pharmacol 170:105-107.
34. 4 receptors. Eur J Pharmacol 290:29-36.
35. 2-adrenoceptors: A cellular and functional characterization. J Pharmacol Exp Ther 297:1-12.
36. Millan MJ, Lejeune F, and Gobert A (2000a) Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: Relevance to the actions of antidepressant agents. J Psychopharmacol 14:114-138.
37. 2-adrenoceptors: II. Influence on monoaminergic transmission, motor function and anxiety in comparison with dexmedetomidine and clonidine. J Pharmacol Exp Ther 295:1206-1222.
38. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, and Newman-Tancredi A (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned, human receptor subtypes. J Pharmacol Exp Ther 303:791-804.
39. 2 receptors elicits prolactin secretion and catalepsy. J Pharmacol Exp Ther 275:885-898.
40. Nagaraja D and Jayashree S (2001) Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. Am J Psychiatry 158:1517-1519.
41. 4.4 receptors: Actions of antiparkinsonian and antipsychotic agents. J Pharmacol Exp Ther 282:181-191.
42. 35S]GTPγS binding. Naunyn-Schmiedeberg's Arch Pharmacol 359:447-453.
43. 35S]GTPγS binding and antibody study. Mol Pharmacol 55:564-574.
44. 2 receptor-mediated G-protein activation in rat striatum: Functional autoradiography and influence of unilateral 6-hydroxydopamine lesions of the substantia nigra. Brain Res 920:41-54.
45. Nicholas AP, Hökfelt T, and Pieribone VA (1997) The distribution and significance of CNS adrenoceptors examined with in situ hybridization. Trends Pharmacol Sci 18:210-211.
46. 3 receptors. Eur J Pharmacol 366:293-300.
47. Quik M, Police S, He L, Di Monte DA, and Langston JW (2000) Expression of D(3) receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: Effect of levodopa treatment. Neuroscience 98:263-273.
48. Rondot P and Ziegler M (1992) Activity and acceptability of trivastal in Parkinson's disease: A multicenter study. J Neurol 239:528-534.
49. 2 receptor agonists with high and low efficacies. Eur J Pharmacol 211:9-14.
50. 2-autoreceptor agonists, with special reference to indolylbutylamines. Drugs Future 15:819-832.
51. 1B adrenergic receptor knockout mice. Increased reaction to novelty and selectively reduced learning capacities. Neurobiol Learning Memory 75:214-229.
52. 1B-adrenoceptors in the motor activity and spontaneous movement of mice. Neuropharmacology 40:254-261.
53. 2-adrenoceptor agonists and antagonists. J Neurochem 68:778-785.
54. 2(short) dopamine receptors. Neuroscience Lett 280:135-138.
55. Troadec JD, Marien M, Darios F, Hartmann A, Ruberg M, Colpaert F, and Michel PP (2001) Noradrenaline provides long-term protection to dopaminergic neurons by reducing oxidative stress. J Neurochem 79:200-210.
56. 2 long receptor-deficient mice display alterations in striatum-dependent functions. J Neurosci 20:8305-8314.
57. 2 receptor isoforms expressed in AtT20 cells differentially couple to G-proteins to acutely inhibit high voltage-activated calcium channels. J Neurochem 73:2375-2382.